Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Authors:
- Georgios VlachogiannisGVGeorgios Vlachogiannis
- Somaieh HedayatSHSomaieh Hedayat
- Yann JaminYJYann Jamin
- Javier Fernández-MateosJFJavier Fernández-Mateos
- Andrea LampisALAndrea Lampis
- Katherine EasonKEKatherine Eason
- Ian HuntingfordIHIan Huntingford
- Rosemary BurkeRBRosemary Burke
- Mihaela RataMRMihaela Rata
- Dow-Mu KohDKDow-Mu Koh
Top Cited Papers
- 23 February 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 359 (6378) , 920-926
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920Keywords
Funding Information
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
This publication has 34 references indexed in Scilit:
- Personalized In Vitro and In Vivo Cancer Models to Guide Precision MedicineCancer Discovery, 2017
- Interrogating open issues in cancer precision medicine with patient-derived xenograftsNature Reviews Cancer, 2017
- Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningeLife, 2016
- Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastasesNature Medicine, 2016
- A Colorectal Tumor Organoid Library Demonstrates Progressive Loss of Niche Factor Requirements during TumorigenesisCell Stem Cell, 2016
- DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?Cancer Discovery, 2016
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer PatientsCell, 2015
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- In vivo assessment of tumoral angiogenesisMagnetic Resonance in Medicine, 2004